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Abstract: The aim of this study was to determine an optimal workflow to detect TP53 mutations in
baseline and longitudinal serum cell free DNA (cfDNA) from high-grade serous ovarian carcinomas
(HGSOC) patients and to define whether TP53 mutations are suitable as biomarker for disease.
TP53 was investigated in tissue and archived serum from 20 HGSOC patients by a next-generation
sequencing (NGS) workflow alone or combined with digital PCR (dPCR). AmpliSeq™-focused NGS
panels and customized dPCR assays were used for tissue DNA and longitudinal cfDNAs, and
Oncomine NGS panel with molecular barcoding was used for baseline cfDNAs. TP53 missense
mutations were observed in 17 tissue specimens and in baseline cfDNA for 4/8 patients by AmpliSeq,
6/9 patients by Oncomine, and 4/6 patients by dPCR. Mutations in cfDNA were detected in 4/6
patients with residual disease and 3/4 patients with disease progression within six months, compared
to 5/11 patients with no residual disease and 6/13 patients with progression after six months.
Finally, mutations were detected at progression in 5/6 patients, but not during chemotherapy. NGS
with molecular barcoding and dPCR were most optimal workflows to detect TP53 mutations in
baseline and longitudinal serum cfDNA, respectively. TP53 mutations were undetectable in cfDNA
during treatment but re-appeared at disease progression, illustrating its promise as a biomarker for
disease monitoring.
Keywords: ovarian cancer; TP53; cell-free DNA; serum; dPCR; next-generation sequencing; molecular
barcoding
1. Introduction
Epithelial ovarian cancer is the most lethal malignancy among gynecological cancers in the
Western world, partly due to the advanced disease stage at the time of diagnosis in most patients [1].
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A large proportion of these patients will have a recurrence or progression within two years and
ultimately die of their disease. Only 30% of women initially diagnosed with advanced-stage disease
will survive more than five years. However, when the disease is diagnosed while still confined to the
ovary, five-year survival is 70% to 90% [2].
Circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) isolated from blood have recently
been extensively investigated as potential blood-based biomarkers for several cancer types [3–5].
In ovarian cancer patients, higher levels of cfDNA were found as compared to healthy donors [6,7]
and patients with benign disease [1]. Higher levels of cfDNA were associated with advanced disease
stage, high grade, and poorer prognosis [1,8]. In addition, it has been reported in an orthotopic mouse
model that progression of disease could be monitored by measuring human cfDNA. In this model, the
amount of cfDNA correlated significantly with tumor weight [9]. However, increased level of cfDNA
can also be found in patients with benign lesions, inflammatory disease, and tissue trauma and is
therefore not a specific tumor biomarker [10]. The presence of tumor-specific genetic alterations in
cfDNA could potentially offer a more specific approach.
In this context, it is of interest that 96% of high-grade serous ovarian carcinomas (HGSOC),
representing the majority of advanced stage ovarian cancers, have a mutated TP53 gene [11,12].
Therefore, the presence of TP53 mutations in cfDNA could potentially be used as a tumor-specific marker
for HGSOC. However, TP53 mutations can also be detected in plasma DNA from healthy, especially
older, individuals and patients with other tumor types [13]. We hypothesized that tumor-specific
TP53 missense mutations in archived serum cfDNA of HGSOC patients could be used as a biomarker
at baseline, and as a marker to monitor tumor load during therapy and thereafter. This hypothesis
is supported by data from a retrospective study of 40 HGSOC patients, which showed that plasma
circulating tumor DNA correlated with disease load at start of therapy. Furthermore, a decrease of less
than 60% in TP53 mutation frequency after one cycle of chemotherapy was associated with shorter
time to progression (TTP) [14]. However, to date, it is not clear which technique is optimal for detecting
and monitoring TP53 mutations in cfDNA.
In the current study, we evaluate different NGS workflows, used alone and combined with digital
PCR (dPCR), for detecting TP53 mutations in minute amounts of archived serum (<1 mL). These
samples were taken at the time of diagnosis from 20 patients with advanced HGSOC patients. The
amount of baseline cfDNA with TP53 mutation was correlated with residual disease after debulking
surgery and progression-free survival after platin-based chemotherapy. We also analyzed mutations
in serum taken during chemotherapy and at disease progression in the same group of patients to
investigate the potential of TP53 mutations in blood as a marker of disease progression.
2. Materials and Methods
2.1. Study Design and Patient Characteristics
For this retrospective study, we selected 20 patients with FIGO stage IIIC–IV ovarian cancer
diagnosed at the Erasmus MC Cancer Institute in Rotterdam, The Netherlands. This retrospective
study of archived tissue and serum was approved by the medical ethics committee of the Erasmus
MC Rotterdam, the Netherlands (MEC-2002-949; MEC-2008-183) and performed in accordance with
the principles of the Declaration of Helsinki and the local law. The study was carried out according
the REMARK guidelines and Code of Conduct of the Federation of Medical Scientific Societies in
the Netherlands (https://www.federa.org/codes-conduct). The majority of patients had high-grade
serous ovarian cancer (N = 19), only one with adenocarcinoma (N = 1). Most patients received primary
or interval debulking surgery, and all received platinum-based chemotherapy. Patient subsets were
defined based on size of residual disease (optimal debulking defined as 0–1 cm vs. non-optimal
debulking defined as >1 cm residual disease) and progression-free survival (PFS ≤ 6 months vs. PFS >
6 months). The study evaluated two workflows (Table 1): Workflow I evaluated only TP53 by NGS and
dPCR on tissue DNA and longitudinal serum cfDNAs, whereas workflow II applied only NGS using
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multigene panels including TP53 on tissue DNA and baseline cfDNA. Patient, clinical characteristics,
and workflow details are summarized in Tables 1 and 2, respectively.
Table 1. Study design and clinical characteristics.
Study Design Details Clinical Characteristics
Patient Workflow SampleSubset Age
FIGO
Stage
Debulking
Surgery *
Residual
Disease
Progression-Free
Survival (PFS)
1
NGS &
dPCR:
TP53 only
Tissue &
longitudinal
cfDNA
43 IV PDS 0–1 cm >6 months
2 37 IIIC PDS 1 cm or more >6 months
3 69 IIIC PDS 1 cm or more >6 months
4 56 IV PDS 0–1 cm >6 months
5 73 IIIC IDS 0–1 cm >6 months
6 ** 53 IIIC PDS 0–1 cm >6 months
7 58 IV PDS 1 cm or more >6 months
8 58 IIIC PDS 0–1 cm >6 months
9 72 IIIC IDS 1 cm or more >6 months
10 ** 75 IV IDS 1 cm or more >6 months
11
NGS only:
Multigene
panels
including
TP53
Tissue &
baseline
cfDNA
47 IV IDS 0–1 cm >6 months
12 47 IIIC IDS 0–1 cm >6 months
13 57 IIIC IDS 0–1 cm >6 months
14 49 IC PDS 0–1 cm >6 months
15 61 IV IDS 0–1 cm >6 months
16 63 IIIC IDS 0–1 cm 0–6 months
17 45 IV IDS 0–1 cm 0–6 months
18 ** 65 IV NA * 1 cm or more 0–6 months
19 47 IV NA * 1 cm or more 0–6 months
20 72 IV IDS 1 cm or more 0–6 months
* PDS = primary Debulking surgery, IDS = interval Debulking surgery, NA = not available. ** Patients were excluded
from cfDNA analysis because their tissue had no TP53 missense mutations.
2.2. DNA Isolation
The DNA was extracted from fresh frozen tumor tissue specimens (N = 8) and from formalin-fixed
paraffin embedded (FFPE) tissue (N = 12) taken at debulking surgery as described previously [15].
Tissues were sectioned for DNA isolation and the percentage of tumor cells was evaluated in a
hematoxylin-eosin-stained section as described earlier [16]. The cfDNA was isolated from archived
minute amounts of serum samples taken at diagnosis for all patients in both workflows, and at
chemotherapy and at disease progression for patients of workflow I. The QIAamp Circulating Nucleic
Acid kit (Qiagen, KJ Venlo, The Netherlands) was used to isolate cfDNA from a median of 400 µL
serum (range 100–1000 µL) according to the manufacturer’s manual. This cfDNA was isolated into
20 µL elution buffer. A Qubit® 2.0 fluorimeter (Thermo Scientific, Carlsbad, California, USA) and the
Quant-iT dsDNA high-sensitivity assay (Invitrogen, Life Technologies, Carlsbad, CA, USA) were used
to quantify the isolated DNA yields and concentrations.
2.3. Next-Generation Sequencing
Different NGS panels and sequencer platforms were used in the two workflows all purchased from
Life Technologies (Carlsbad, CA, USA). The panels differ in amplicon and target size, methodology, and
sequencing costs per sample (Table 2). Tissue DNA was sequenced on the Ion Torrent Personal Genome
Machine (ion-PGM) using two Ion Ampliseq focused panels. In workflow I, the Ion AmpliSeq™
TP53 community panel (24 amplicons, 2550 bp; analyzing exons and UTRs of the TP53 gene) was
used. In workflow II, a customized Ion Ampliseq Diagnostic V5.1 targeted panel (328 amplicons,
35,793 bp, 41 genes) was applied to sequence all TP53 exons. Serum cfDNA was sequenced with
the Ion AmpliSeq™ TP53 community panel on the ion-PGM (workflow I) or with the Oncomine
breast cfDNA NGS assay with molecular barcoding (26 amplicons, 4420 bp, 10 genes) on an Ion S5XL
sequencer (workflow II). The ampliseq panels have a limit of detection (LOD) for mutation frequencies
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of at least 1%, whereas the Oncomine panel has a LOD of 0.1% at 20 ng DNA input. For this lower
LOD, much deeper read depth coverage is needed for the Oncomine panel (>20k coverage) than
Ampliseq panels (<1k coverage). Consumables, kits, software packages, and protocols for the NGS
analyses with Ampliseq and Oncomine focused panels were used as indicated by the manufacturer
and as previously described by us [3,16,17]. Briefly, 10 ng tumor DNA was used for all patients as
input in the Ampliseq library preparation. For cfDNA library preparations, at least 1.5 ng cfDNA
was used with equal amounts for all three sera per patient for the Ampliseq panel in workflow I
(median 2.2 ng; range per patient: 1.5–3.3 ng) and at least 15 ng up to 20 ng of cfDNA was used for the
Oncomine panel in workflow II. Samples were sequenced on Ion 318 and 530 chips for workflows I
and II, respectively. Sequencing with Ampliseq panels was performed with on average tumor tissue
DNA reads depth coverage of 1725 reads/amplicon (range: 943–3584 reads) for workflow I and 1166
reads/amplicon (range: 430–1796 reads) for workflow II. The average cfDNA reads depth coverage
was 1851 reads/amplicon (range: 843–3776 reads) for workflow I and 32,902 reads/amplicon (range:
5786–59,976 reads) for workflow II.
Table 2. Cell-free DNA (cfDNA) workflow details.
Worflow I:
NGS & dPCR—TP53 only
Worflow II:
NGS only—Multigene Hotspot Panels
Including TP53
Samples Tissue DNA LongitudinalcfDNA Tissue DNA Baseline cfDNA only
NGS panel names &
details
Ampliseq TP53
community panel
Ampliseq TP53
community panel
Ampliseq
Customized
Diagnostic panel
Oncomine breast
cfDNA assay with
molecular barcoding
Panel details 24 amplicons,2550 bp
328 amplicons,
35793 bp, 41 genes
26 amplicons, 4420 bp,
10 genes
Input amount 10 ng 1.5–3.3 ng 10 ng 15–20 ng
Mean reads depth
coverage (range)
1725
reads/amplicon
(943–3584 reads)
1851
reads/amplicon
(843–3776 reads)
1166 reads/amplicon
(430–1796 reads)
32902 reads/amplicon
(5786–59976 reads)
Estimated costs per
sample for:
NGS €150–€250 €150–€250 €250–€350 €350–€450
dPCR
(€400 per mutation
assay)
€20–€30 €20–€30 NA NA
Workflow cfDNA NGS
vs. dPCR total costs for:
Baseline cfDNA only €150–€250 vs.€420–€430
€350–€450 vs.
€420–€430
cfDNA at baseline &
progression
€300–€500 vs.
€440–€460
€700–€900 vs.
€440–€460
3 longitudinal cfDNAs €450–€750 vs.€460–€490
€1050–€1350 vs.
€460–€490
5 longitudinal cfDNAs €750–€1250 vs.€500–€550
€1750–€2250 vs.
€500–€550
2.4. Bio-Informatics for SNV Detection and Evaluation
The Torrent Suite v4.0 (Thermo Scientific, Carlsbad, CA, USA) was used for raw data analyses, base
calling, and alignment. Variant Caller v4.4.2.1 (VC, Thermo Scientific, Carlsbad, CA, USA) was applied
to detect DNA sequence alterations. Annotation of the variants was performed by a custom pipeline
including ANNOVAR (openbioinformatics.org/annovar) in a Galaxy (galaxyproject.org) environment.
For the initial VC analysis of each tumor and serum DNA-sample, somatic low-stringency filter
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settings were applied to detect DNA variants when compared to the reference genome (hg19; build
37). For each sample, only sequences with 100 reads depth or more were evaluated. Subsequently,
TP53 mutations were visually examined using Integrative Genomics Viewer (IGV, CA, USA) software
(http//www.broadinstitute.org/igv).
2.5. Digital PCR
Independent validation of six identified TP53 mutations were performed using TaqMan® SNP
genotyping assays on the QuantStudio™ 3D Digital PCR system (Thermo Fisher Scientific, Waltham,
MA, USA), according to the manufacturer specifications. All the assays, except TP53 p.R282W, were
designed in-house using the Thermo Fisher Custom TaqMan® Assay Design Tool and ordered as
Custom TaqMan® SNP Genotyping assay from Thermo Fisher (Supplementary Tables S1 and S2). The
PCR reaction mix was prepared in a final volume of 17.4 µL containing 30 ng of tumor DNA or ranging
from 3.6 ng to 20 ng for serum cfDNA. Then, the amplification mix was partitioned into ~20,000 wells
loaded in a QuantStudio 3D Digital PCR Chip v2 and run on a ProFlex 2x Flat PCR System. The
temperature profile for amplification was: An activation step of 10 min at 96 ◦C, followed by 40 cycles
of 2 min at 60 ◦C, 30 s incubation at 98 ◦C, 2 min at 60 ◦C, and pause at 10 ◦C. The QuantStudio™ 3D
analysisSuite™ was used to analyze the end-point fluorescence data to determine the proportion of
templates, with and without a mutation, and to calculate the Mutation Allele Frequency (MAF). At
least one negative and one positive control were added to each run.
2.6. TP53 Immunohistochemistry
FFPE tumor tissue sections of patients 1 and 2 were stained with polyclonal p53 antibodies clone
DO-1 (1:200, Santa Cruz Biotechnogy, Heidelberg, Germany) and DO-7 (1:100, Dako, Santa Clara,
USA) as described previously [18]. The DO-1 and DO-7 recognize overlapping epitopes. For patients
3–20, mouse monoclonal p53 antibody Bp53-11 (Ventana 769-2541, Ventana Medical Systems, Roche,
Tuscon, AZ, USA) was used. Detection was performed using Ventana Benchmark Ultra detective with
Ultraview Universal DAB detection kit (Ventana 760-500, Ventana Medical Systems, Roche, Tuscon,
AZ, USA) and antigen retrieval Cell Conditioning Solution (CC1) (Ventana 950-124, Ventana Medical
Systems, Roche, Tuscon, AZ, USA). The p53 expression was scored as previously described by Kobel
et al. [19] and categorized into overexpression, complete absence, cytoplasmic, or wild-type.
2.7. Statistics
The study complied with reporting recommendations for tumor marker prognostic studies
(REMARK) criteria [20]. Samples were called positive for TP53 non-synonymous mutations when the
mutation frequency was above 1% when detected by Ampliseq panels or above 0.1% when detected
by Oncomine or digital PCR assays. Statistical analyses were performed with Microsoft and Simple
Interactive Statistical Analysis (SISA; http://www.quantitativeskills.com/sisa/index.htm). The analyses
included student t-tests for continuous variables, Chi-square test for categorical variables. p-values
were two-sided, and significance was defined at <0.05.
3. Results
3.1. TP53 Mutation and Protein Expression Analysis in Tumor Tissue
First the TP53 mutation status and protein expression were analyzed in tumor tissues. As
TP53 mutations in our archived serum not only might originate from tumor cells, but can also
arise from clonal hematopoiesis, we first defined tumor-specific TP53 mutations in tissue by NGS
and immunohistochemistry. Missense TP53 mutations and strong nuclear p53 protein expression
were detected in all but three patients with no or synonymous mutations (Table 3, Figure 1). Only
non-synonymous TP53 mutations with (aberrant) nuclear staining in tumor tissue were then evaluated
in serum cfDNA.
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Table 3. Tumor tissue and serum characteristics.
cfDNA Yields per mL
Serum (ng/mL)
cfDNA MAF
(NGS)
cfDNA MAF
(dPCR)
Subset Patient
Identified
TP53
Mutation in
Tissue
MAF
Tissue TP53 IHC D C P
Excludedin
cfDNA
Analysis
D P D P AdditionalMutation(s) MAF
I. NGS &
dPCR:
TP53 only
1 p.Y163C 57% nuclear ++ 17 16 56 0.0% 0.0% 0.0% 0.8%
2 p.C275Y 27% nuclear ++ 30 56 44 1.0% 0.0% 5.3% 0.1%
3 p.P151R 73% nuclear ++ 148 30 55 0.0% 6.0% NE NE
4 p.R282W 78% nuclear ++ 37 39 64 30.0% 0.0% 31.9% 0.4%
5 p.K132R 21% nuclear ++ 35 40 35 1.0% 1.0% 2.6% 1.8%
6 No mutation - cytoplasmatic 52 28 46 no mutation - - - -
7 p.Y163C 64% nuclear ++ 56 46 39 2.0% 1.0% 6.2% 2.9%
8 p.C275Y 7% nuclear ++ 119 35 84 0.0% 0.0% 0.0% 0.0%
9 p.C277F 58% nuclear ++ 111 44 275 0.0% 0.0% NE NE
10 p.N131N 3% cytoplasmatic 229 106 338 synonymous - NE NE
II. NGS
only:
Multigene
hotspot
panels
including
TP53
11 p.E286G 81% nuclear ++ 174 1.9%
12 p.Y205D 51% nuclear ++ 174 0.0%
13 p.F134V 75% nuclear ++ 102 0.0% TP53p.T253I 0.1%
14 p.K132R 79% nuclear ++ 265 0.0%
15 p.L194R 88% nuclear ++ 83 0.3%
16 p.Y220C 65% nuclear ++ 98 0,0% ESR1p.R394S 0.3%
17 p.C176W 56% nuclear ++ 71 25.6%
18 Unknown - N/A 628 unknown -
19 p.E258G 85% nuclear ++ 264 0.6%
20 p.P278S 60% nuclear ++ 107 0.5% PIK3CAp.H1047R 1.3%
IHC = immunohistochemistry, D = at diagnosis, C = after chemotherapy, P = at disease progression, NGS = next generation sequencing, dPCR = digital PCR, MAF = mutant allele
frequency, unknown = mutation was unknown since no tissue was available, N/A = not available, ++ = high TP53 levels nuclear staining.
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Figure 1. Tissue p53 staining. Two examples of immunohistochemical localization of p53 expression 
in patients with advanced stage ovarian cancer. Staining of sporadic nuclei with p53 antibody is seen 
in the stroma in both figures, acting as internal control. The p53 expression showed strong nuclear 
staining in patient 5 with a TP53 p.K132R mutation (left figure) and cytoplasmic staining in patient 6 
without a TP53 mutation (right figure). 
3.2. Serum cfDNA Yields at Diagnosis and Over Time 
The cfDNA yield per mL serum showed a range between 16 and 338 ng for workflow I and 
between 71 and 628 ng for workflow II (Table 3). Median cfDNA yields at diagnosis were comparable 
between non-optimal debulked patients (130ng/mL (N = 8)) and optimally debulked patients (90 
ng/mL (N = 12); p = 0.218), and between patients with PFS shorter vs. longer than six months (median 
107 (N = 5) and 102 ng/mL (N = 15); p = 0.30) (Figure 2A,B). The longitudinal serum cfDNA yields in 
workflow I were overall lower during chemotherapy (median: 39 ng/mL; p = 0.108) but similar at 
disease progression (median: 55 ng/mL; p = 0.627) when compared to cfDNA yields at diagnosis 
(median: 54 ng/mL) (Figure 2C). 
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3.3. Serum TP53 Mutation Detection at Diagnosis
In 9/17 patients (53%) with a TP53 missense mutation in tumor tissue, the mutation was also
identified in serum cfDNA at diagnosis (Table 3; Supplementary Figure S1). These mutations were
detected in 4/8 patients (50%) by Ampliseq NGS and in 4/6 patients (67%) by digital PCR for workflow
I, and by Oncomine NGS in 6/9 patients (67%) for workflow II. dPCR was not performed at diagnosis
for patients examined in the latest group due to the low amount of cfDNA available. Overall, TP53
mutations in serum derived cfDNA at diagnosis were significantly more observed in patients with
FIGO stage IV disease (p = 0.024; Table 4) but not related to other parameters including cfDNA yields
or tumor tissue TP53 mutation frequencies (Table 4). Although not statistically significant, the number
of patients with mutations detected in serum at diagnosis was higher in patients with non-optimal
debulking surgery (4/6 patients (67%)) and disease progression within six months (3/4 patients (75%))
compared to patients with optimal debulking (5/11 patients (45%)) or progression after six months
(6/13 patients (46%)). These exploratory findings should be verified in a larger set of patients.
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were not significantly different. (c) Graph showing the Log cfDNA concentration (ng/mL of serum) 
isolated from 10 patients at three different time points. Data points correspond to total cfDNA yields 
per mL serum for each patient (Pt) at the three different time points from serum collection: At 
diagnosis (D), after chemotherapy (C), and at disease progression (P). 
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Figure 2. Serum cfDNA yields isolated from patients with advanced ovarian cancer. Boxplots presenting
(a) amounts of cfDNA (ng/mL of serum) isolated at diagnosis for patients in relation to residual disease
(RD; no or less than 1 cm vs. 1 cm or more) and (b) progression-free survival (PFS; ≤6 months and
>6 months). The individual measurements are shown as dots, the mean by the cross (x), and median
as horizontal line within the box. The cfDNA amounts between the groups of patients were not
significantly different. (c) Graph showing the Log cfDNA concentration (ng/mL of serum) isolated
from 10 patients at three different time points. Data points correspond to total cfDNA yields per mL
serum for each patient (Pt) at the three different time points from serum collection: At diagnosis (D),
after chemotherapy (C), and at disease progression (P).
Table 4. Comparison clinicopathological characteristics of high-grade serous ovarian carcinomas
(HGSOC) patien s with and without serum tumor-specific TP53 mutation at diagnosis.
HGSOC Patient Seru cfDNA at Diagnosis:
Without Tumor-Cpecific
TP53 Mutation
With Tumor-Specific
TP53 Mutation p-Value
Number of patients 8 9
Average TP53 mutation allele frequency
(MAF in %):
in tumor tissue 58% 62% 0.819
in cfDNA 0% 7% 0.115
NGS workflow (N):
I 4 4 0.819
II 4 5
Age at diagnosis (average): 57 55 0.703
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Table 4. Cont.
HGSOC Patients Serum cfDNA at Diagnosis:
Without Tumor-Cpecific
TP53 Mutation
With Tumor-Specific
TP53 Mutation p-Value
FIGO Stage (N):
IC 1 0 0.024
IIIC 6 2
IV 1 7
Debulking surgery (N):
PDS 4 3 0.614
IDS 4 5
Residual Disease (N):
0–1 cm (optimal debulking) 6 5 0.402
1 cm or more (non-optimal debulking) 2 5
Progression-Free Survival (PFS):
0–6 months (n) 1 3 0.312
>6 months (n) 7 6
average cfDNA yield (ng/mL serum):
at diagnosis 129 95 0.363
after chemotherapy 31 45 0.106
at progression 117 45 0.268
TP53 mutation at progression measured by
dPCR (N):
Yes 1 4 0.079
No 1 0
Other gene mutations detected in cfDNA at
diagnosis:
PIK3CA p.H1047R 1.30%
ESR1 p.R394S 0.30%
TP53 p.T253I * 0.10%
PDS = primary Debulking surgery, IDS = interval Debulking surgery, NGS = next generation sequencing, dPCR =
digital PCR, N = number of patients, * = TP53 p.T253I was identified in serum but not in tumor tissue.
3.4. Monitoring TP53 Mutations Over Time
AmpliSeq NGS and dPCR were applied in workflow I to detect TP53 mutations in sera taken
during chemotherapy and at disease progression (Supplementary Figure S2). Both methods were
unable to identify mutations during chemotherapy (not shown) but mutations were detected at disease
progression in 3/8 patients (38%) by Ampliseq and in 5/8 patients (63%) by dPCR. The cfDNA TP53
allele frequencies were lower at progression compared to baseline at diagnosis for all patients except
patient 1 (Table 3). Interestingly, one patient with a TP53 mutation at progression had this mutation not
detected at diagnosis (Table 3). Further longitudinal monitoring of cfDNA was performed for patient 5
by the evaluation of CA125 levels and the dPCR monitoring of TP53 p.K132R in cfDNA derived from
additional sera. Low CA125 levels were measured between 5 and 10 months, whereas cfDNA levels
increased upon disease progression (Figure 3).
3.5. cfDNA Workflow Comparison
Next to assay detection sensitivity, setup and costs are also important parameters to define an
optimal workflow for monitoring TP53 mutations in blood for (routine) cfDNA evaluation. First,
Oncomine-NGS and dPCR (67%) were more sensitive assays than Ampliseq-NGS (50%) for detection
of TP53 mutations in baseline cfDNA. The workflows (Table 2) differed in setup to evaluate TP53
only by NGS or combined with dPCR (workflow I) or multiple genes including TP53 by NGS only
(workflow II). Secondly, the setup is important, since dPCR is only applicable when the patient-specific
TP53 mutation is known from tumor tissue by Ampliseq-NGS or from cfDNA by Oncomine-NGS.
Moreover, NGS enables the detection of additional mutations for TP53 (workflow I) or for other genes
as well (workflow II, Table 3), which might be acquired over time in longitudinal cfDNAs. Finally,
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current estimated costs differ between the two workflows and the applied setup. NGS only will be
more expensive than tissue DNA NGS combined with dPCR of cfDNA (Table 2). For example, analyses
of three longitudinal cfDNAs will cost €450–€750 by Ampliseq-NGS, €1050–€1350 by Oncomine NGS,
whereas dPCR costs €460–€490 including €400 for designing the patient-specific TP53 mutation assay.
The differences in costs between NGS and dPCR will increase much more when more longitudinal
cfDNAs are evaluated. Workflow I with dPCR is only more cost-effective than NGS when at least 2
cfDNA samples are evaluated.
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4. Discussion
In the current study, we investigated two NGS workflows to detect TP53 mutations in tissue and
serum cfDNA derived from patients with advanced stage serous ovarian cancer. Our aim was to
establish the best method and to study whether TP53 mutations can be used as a tumor biomarker in
liquid biopsies. Patient-specific TP53 missense mutations were identified by targeted NGS in tumor
tissue and subsequently analyzed by NGS alone or in combination with dPCR in serum cfDNA taken
at different timepoints.
The tumor suppressor TP53 gene is mainly mutated in exons 4–9, encoding for the DNA-binding
domain of the protein [21]. It has been demonstrated that the aberrant protein is able to influence tumor
progression toward migration, invasion, and metastasis in different tumor types [22–26]. In our study,
85% of patients harbored non-functional TP53 alterations in tumor tissue, which is in keeping with
previous studies reporting TP53 mutations in more than 80% of HGSOC [27–29]. It has been shown by
Kang et al. that HGSOC patients carrying a gain-of-function mutant p53 frequently develop resistance
against platinum-based treatment as well as being more prone to develop distant metastasis [30].
Therefore, it seems that TP53 mutations might play a key role in the tumorigenesis of HGSOC.
Levels of cfDNA can vary widely in cancer patients as reported by Fleischhacker and Schmidt [31,32].
These authors reviewed 34 different studies and found that, although the cfDNA concentration in cancer
patients is usually much higher than healthy controls, the amount varies widely and is often below
100 ng/mL. Our results are in line with these studies as the cfDNA yields measured at diagnosis were
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widely variable, although in 55% of cases, the yield was above 100 ng/mL. Yields of cfDNA in blood
taken after chemotherapy and progression were, however, lower than 100 ng/mL in almost all cases.
Previous studies have demonstrated a correlation between tumor burden and cfDNA yields. It was
shown that highly proliferative lesions release more cfDNA [33,34]. Other studies demonstrated that
cfDNA amounts correlated with cancer survival rates [35], and showed its diagnostic value in different
tumor types, such as lung cancer [36]. In contrast, we observed in our patient subset no significant
differences in serum cfDNA amounts at diagnosis and over time in relation to clinical disease parameters.
Since cfDNA from tumor cells is released in the blood, the cfDNA mutational status may reflect
the genetic characteristics of the primary or metastatic lesion [37,38]. Previous studies by Diaz and
Bardelli demonstrated that mutations present in tumor tissue are virtually the same as those present
in the cfDNA fraction [39,40]. Tumor-specific mutations in cfDNA could therefore act as prognostic
and/or predictive biomarkers for cancer patients. In our study, we were able to detect the missense
TP53 point mutation present in the primary tumor in cfDNA in 67% of patients. These results are in
agreement with previous studies showing that point mutations in TP53 can be also measured in the
serum DNA of patients with ovarian cancer [1]. In general, these results highlight the potential of
cfDNA as diagnostic tool for ovarian cancer [5,12]. Our small cohort of HGSOC patients with FIGO
stage IV disease showed a relation between levels of TP53 mutations detected in serum cfDNA at
diagnosis but less with residual disease or disease progression.
Due to the small amounts of cfDNA and cfDNA available in blood, especially from retrospective
archived serum, research is currently focused on the development of new strategies to quantify and
characterize cfDNA. Sensitivity and specificity are the main challenges for detecting cancer-specific
alterations in cfDNA. Recent advances in NGS [41–43] and PCR protocols have allowed the quantitative
detection of mutations with a sensitivity below 0.001% [44]. Compared to conventional PCR, dPCR is a
reliable method and easy to set up. Using this method, it is possible to quantify cfDNA without external
references and with a higher sensitivity, precision, efficiency, and reproducibility [40]. In contrast, NGS
allows identification of novel genetic or epigenetic mutations. Conventional NGS methods, however,
are not as sensitive as dPCR methods and mutations could be missed, particularly when the total
number of reads is low. Therefore, researchers have combined the use of NGS and dPCR protocols for
liquid biopsy. When comparing the cost and time required for the different techniques, dPCR workflow
is much cheaper because it needs less consumables and turnaround time to monitor a specific mutation
in follow-up studies compared to NGS protocols. Moreover, dPCR enables accurate quantification of
mutant DNA within vast amounts of wild-type DNA, i.e., low mutant allele frequencies (>0.1%), and
is often used for the independent validation of NGS results.
Overall, Oncomine NGS in workflow II and dPCR in workflow I enabled detection of TP53
mutations below 1% allele frequencies and were more sensitive than the conventional Ampliseq NGS.
This resulted in the detection of mutations in 67% of patients by dPCR and Oncomine NGS compared to
only 50% of patients by Ampliseq NGS. Moreover, to trace TP53 mutations for disease monitoring in
multiple longitudinal serum derived cfDNA, we showed that dPCR is better compared to Oncomine
NGS, due to lower amounts for cfDNA needed and lower overall costs. However, a proper direct
comparison of mutation detection sensitivity of each platform was not possible due to the limitations of
our study design. Summarizing, study restrictions were the limited amounts of archived serum available
(>1mL), low cfDNA yields, and different (recommended) cfDNA input amounts for each NGS platform.
To accomplish an accurate comparison of detection sensitivities, equal cfDNA input amounts should be
evaluated by both NGS platforms in future studies. We also compared the cost-effectiveness of the two
workflows, which is of relevance when introducing the methodology to routine diagnostic of HGSOC.
To date, several clinical studies have tried to link TP53 mutations with patient survival or the
development of chemoresistance [45]. However, the conclusions of these studies are often contradictory
due to the unselective classification of all TP53 mutations and the single use of immunohistochemistry
to determine the TP53 mutational status. Recently, it has been proposed that TP53 mutations could be
used as biomarkers to predict patient response to chemotherapy. In line with these studies, we were
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unable to identify TP53 mutations at chemotherapy but detected these mutations at disease progression
for 5/6 patients. Parkinson et al. [14] reported that cfDNA TP53 mutant allele fraction and volumetric
measurements were correlated in HGSOC patients, particularly in a subset of patients without ascites.
Moreover, almost all subjects with disease volume larger than 32 cm3 showed higher cfDNA copies.
A rapid response to chemotherapy was more closely related to cfDNA than to CA-125. These results
strongly suggest that cfDNA has the potential to be a highly specific early molecular response marker
in HGSOC [14,40].
5. Conclusions
In conclusion, detection of tumor-specific TP53 missense mutations in minute amounts of archived
serum-derived cfDNA from HGSOC patients is enabled by dPCR or NGS. Our exploratory finding
that TP53 mutations present at diagnosis became undetectable in cfDNA after chemotherapy but
re-appeared at disease progression highlights the potential role of TP53 missense mutations as a
biomarker for clinical disease monitoring in ovarian cancer. However, detection sensitivities of NGS
platforms need to be validated further in a larger study.
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